Marshall Wace
PLX icon

Marshall Wace’s Protalix BioTherapeutics PLX Stock Holding History

Marshall Wace’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,079
Closed -$34.3K – 3580
2025
Q4 		$34.3K Buy
+19,079
New +$39K ﹤0.01% 2802
2025
Q2 		– Sell
-615,085
Closed -$1.57M – 3055
2025
Q1 		$1.57M Buy
615,085
+513,186
+504% +$1.23M ﹤0.01% 1574
2024
Q4 		$192K Buy
+101,899
New +$144K ﹤0.01% 2364
2023
Q3 		– Sell
-562,139
Closed -$1.12M – 2565
2023
Q2 		$1.12M Buy
562,139
+411,781
+274% +$981K ﹤0.01% 1663
2023
Q1 		$316K Buy
+150,358
New +$264K ﹤0.01% 2281

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Marshall Wace's PLX Position: Q1 2026 in Review

Marshall Wace sold out of Protalix BioTherapeutics (PLX) in Q1 2026, closing a stake of 19,079 shares — an estimated $34.3K sold.

Marshall Wace first reported a position in PLX in Q1 2023 and held it in 5 quarters. The position peaked at $1.57M in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Marshall Wace reported no remaining Protalix BioTherapeutics position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 19,079 Protalix BioTherapeutics shares in Q1 2026, an estimated $34.3K.
  • Marshall Wace first reported a position in Protalix BioTherapeutics in Q1 2023 and held it in 5 quarters.
  • Marshall Wace's Protalix BioTherapeutics position peaked at $1.57M in Q1 2025.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.